We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Key TxCell patent to be granted in Japan for its lead product Ovasave®
News

Key TxCell patent to be granted in Japan for its lead product Ovasave®

Key TxCell patent to be granted in Japan for its lead product Ovasave®
News

Key TxCell patent to be granted in Japan for its lead product Ovasave®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Key TxCell patent to be granted in Japan for its lead product Ovasave®"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TxCell SA has announced that the Japan Patent Office has indicated that it intends to grant to TxCell a key patent in Japan to cover its lead product Ovasave® and its application to inflammatory bowel disease (IBD). Specifically, the patent covers the administration of a composition that consists of at least one human Type-1 Treg cell population directed against a food antigen from the common human diet.

The equivalent patent has already been granted in the USA (2015), Australia (2015) and Russia (2013). Other corresponding patent applications for Ovasave in IBD are pending in major markets globally. TxCell now owns or controls more than 126 patents that provide coverage for its first platform ASTrIA. These patents are related to the characterisation, production and use of Ag-Tregs for the treatment of chronic autoimmune inflammatory diseases.

"Recent positive developments in both the regulatory field and product approvals means that
Japan has become a key market for cellular immunotherapy,” said Stéphane Boissel, Chief
Executive Officer of TxCell. “The grant of this latest key patent in Japan will help to achieve
TxCell’s ambitious objectives in expanding our global reach.

In addition, TxCell has dedicated years of effort in research and development to establish a robust international intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need.”

Advertisement